<DOC>
	<DOCNO>NCT01316250</DOCNO>
	<brief_summary>The result International Randomized Study Interferon STI571 ( IRIS ) trial indicate patient chronic phase CML treat first line imatinib , achievement complete partial cytogenetic response ( CCyR PCyR ) 12 month associate significantly well progression-free survival ( PFS ) . Second generation tyrosine kinase inhibitor nilotinib overcome imatinib resistance great potency bind BCR-ABL . Recent result indicate , patient previously untreated chronic phase CML , nilotinib result faster high rate CCyR PCyR imatinib . However , nilotinib use associate diet restriction much high financial cost . The primary objective study evaluate ability imatinib maintain complete cytogenetic response ( CcyR ) patient achieve CCyR 12 month first-line treatment nilotinib .</brief_summary>
	<brief_title>Gleevec Maintenance Therapy After Cytogenetic Response With Nilotinib Newly Diagnosed Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>Imatinib mesylate selectively target causative BCR-ABL oncogene CML . The result IRIS trial indicate patient chronic phase CML treat first line imatinib , achievement complete partial cytogenetic response ( CCyR PCyR ) 12 month associate significantly good progression free survival ( PFS ) . Second generation tyrosine kinase inhibitor nilotinib overcome imatinib resistance great potency bind BCR-ABL . Recent result indicate , patient previously untreated chronic phase CML , nilotinib result faster high rate CCyR PCyR imatinib . However , nilotinib use associate diet restriction much high financial cost . Hence , appeal strategy achieve high rate CCyR first line nilotinib maintain response long term imatinib user friendly cost-effective . The primary objective test ability imatinib maintain cytogenetic response patient achieve CCyR PCyR 12 month first line nilotinib . The secondary aim assess effect strategy molecular response , BCR-ABL mutation , CML progenitor .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Newly diagnose untreated Philadelphia chromosomepositive CML ( use hydroxyurea &lt; 3 month allow ) chronic phase define follow criterion : &lt; 15 % blast peripheral blood ( PB ) &amp; bone marrow ( BM ) &lt; 30 % blast plus promyelocytes PB &amp; BM &lt; 20 % basophil PB ≥100 x 109/L platelet No evidence extramedullary involvement , exception liver &amp; spleen 2 . Patients ( pt ) ≥18 yrs age 3. WHO Performance Status ≤2 4 . Pts must follow laboratory value : Potassium within normal limit correct within normal limit supplement prior first dose study medication Total calcium ( correct serum albumin ) magnesium within normal limit correctable supplement Phosphorus ≥ low limit normal ( LLN ) correctable supplement ALT AST ≤2.5 x upper limit normal ( ULN ) ≤5.0xULN consider due tumor Alkaline phosphatase ≤2.5xULN Serum bilirubin ≤1.5xULN Serum Cr ≤1.5xULN 24hour Cr Cl ≥50 ml/min Serum amylase ≤1.5xULN serum lipase ≤1.5xULN 5 . Written sign inform consent prior study procedure 1 . Cytopathologically confirmed central nervous system ( CNS ) infiltration 2 . Impaired cardiac function , include one following : Left ventricle ejection fraction ( LVEF ) &lt; 45 % institutional low limit normal range ( whichever high ) determine MUGA scan echocardiogram Complete leave bundle branch block Use pacemaker ST depression &gt; 1mm 2 lead and/or T wave inversion 2 contiguous lead Congenital long QT syndrome History presence significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beats/min ) QTc &gt; 450 msec screen ECG Right bundle branch block plus leave anterior hemiblock , bifascicular block Myocardial infarction within 12 month prior start nilotinib Unstable angina diagnose treat past 12 month Other clinically significant heart disease ( e.g. , congestive heart failure , uncontrolled hypertension , history labile hypertension ) 3 . Use therapeutic coumarin derivative ( i.e. , warfarin , acenocoumarol ) day study drug administration 4 . Acute chronic liver renal disease consider unrelated tumor active Hepatitis A , B , C 5 . Other concurrent severe and/or uncontrolled medical condition 6 . Pts currently receive treatment medication potential prolong QT interval 7 . Pts receive investigational drug ≤4 week investigational cytotoxic agent within 1 week ( within 5 halflives previous investigational cytotoxic agent ) prior start study drug recover side effect therapy 8 . Pts receive wide field radiotherapy ≤4 week limit field radiation palliation &lt; 2 week prior start study drug recover side effect therapy 9 . Pts undergone major surgery ≤2 week prior start study drug recover side effect therapy 10 . Known diagnosis HIV 11 . Pt history another malignancy currently clinically significant currently require active intervention 12 . Pts pregnant breast feeding , adult reproductive potential employ effective method birth control ( woman childbearing potential must negative serum pregnancy test within 48 hrs prior drug administration ) . Post menopausal woman must amenorrheic least 12 month . Male &amp; female pt must agree employ effective method birth control throughout study 3 month follow discontinuation study drug 13 . Pts unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>nilotinib</keyword>
	<keyword>complete cytogenetic response</keyword>
	<keyword>imatinib mesylate</keyword>
</DOC>